Article

Antibody responses to SARS-CoV-2 variants LP.8.1, LF.7.1, NB.1.8.1, XFG and BA.3.2 following KP.2 monovalent mRNA vaccination

2025-08-27

Abstract excerpt

<h4>ABSTRACT</h4> The evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in antigenically distinct variants that challenge vaccine-induced immunity. The KP.2 monovalent mRNA vaccine was deployed in 2024 to address immune escape by emerging SARS-CoV-2 subvariants. We assessed neutralizing antibody responses in 56 adults with varied exposure histories following KP.2 vaccination a...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: d83bd335-041f-5109-9245-47a22910428a
DOI: 10.1101/2025.08.24.25333689

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Antibody responses to SARS-CoV-2 variants LP.8.1, LF.7.1, NB.1.8.1, XFG and BA.3.2 following KP.2 monovalent mRNA vaccinationDOI 10.1101/2025.08.24.25333689Read

Immunological imprinting shapes the cross-reactive antibody responses to the KP.2 and LP.8.1 vaccine dosesSemantic proximity Read

Characterizing SARS-CoV-2 neutralization profiles after bivalent boosting using antigenic cartographySemantic proximity Read

Impact of LP.8.1-Adapted mRNA Vaccination on SARS-CoV-2 Variant NeutralisationSemantic proximity Read

Differential antibody dynamics to SARS-CoV-2 infection and vaccinationSemantic proximity Read

Ongoing evolution of SARS-CoV-2 drives escape from mRNA vaccine-induced humoral immunity.Semantic proximity Read

Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccinationSemantic proximity Read

SARS-CoV-2 mRNA Vaccine Induces Robust Specific and Cross-reactive IgG and Unequal Strain-specific Neutralizing Antibodies in Naïve and Previously Infected RecipientsSemantic proximity Read

Characterizing SARS-CoV-2 neutralization profiles after bivalent boosting using antigenic cartographySemantic proximity Read

Bivalent and Monovalent SARS-CoV-2 Variant Vaccine Boosters Improve coverage of the known Antigenic Landscape: Results of the COVID-19 Variant Immunologic Landscape (COVAIL) TrialSemantic proximity Read

Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variantsSemantic proximity Read

SARS-CoV-2 mRNA Vaccine Induces Robust Specific and Cross-Reactive IgG and Unequal Strain-Specific Neutralizing Antibodies in Naïve and Previously Infected RecipientsSemantic proximity Read

Humoral waning kinetics against SARS-CoV-2 is dictated by disease severity and vaccine platformSemantic proximity Read